Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.

PURPOSE Hot flashes represent a substantial clinical problem for some breast cancer survivors. Although estrogen or progesterone preparations can alleviate these symptoms in many patients, concern remains regarding the use of hormonal preparations in such women. Thus, there is a perceived need for nonhormonal treatments for hot flashes for breast cancer survivors. Based on anecdotal evidence that vitamin E was helpful, we designed a trial to investigate this matter. METHODS We developed and conducted a placebo-controlled, randomized, crossover trial where, after a 1 week baseline period, patients received 4 weeks of vitamin E 800 IU daily, then 4 weeks of an identical-appearing placebo, or vice versa. Diaries were used to measure potential toxicities and hot flashes during the baseline week and the two subsequent 4-week treatment periods. RESULTS The 120 patients evaluated for toxicity failed to show any. The 105 patients who finished the first treatment period showed a similar reduction in hot flash frequencies (25% v 22%; P = .90) for the two study arms. A crossover analysis, however, showed that vitamin E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P < or = .05). At the study end, patients did not prefer vitamin E over the placebo (32% v 29%, respectively). CONCLUSION Although this trial was able to show a statistically significant hot flash reduction with vitamin E compared to a placebo, the clinical magnitude of this reduction was marginal.

[1]  K. Helzlsouer,et al.  Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Lamb Effects of cancer on the sexuality and fertility of women. , 1995, Seminars in oncology nursing.

[3]  J. O'fallon,et al.  Megestrol acetate for the prevention of hot flashes. , 1994, The New England journal of medicine.

[4]  Stephen Senn,et al.  Cross-over trials in clinical research , 1993 .

[5]  D. Serr,et al.  Endocrinological basis of hot flushes. , 1989, Obstetrical & gynecological survey.

[6]  M. Kenward,et al.  Design and Analysis of Cross-Over Trials , 1989 .

[7]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[8]  J. Ubachs,et al.  Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. , 1987, Maturitas.

[9]  R. Casper,et al.  NEUROENDOCRINOLOGY OF MENOPAUSAL FLUSHES: AN HYPOTHESIS OF FLUSH MECHANISM , 1985, Clinical endocrinology.

[10]  R. Cutick Special needs of perimenopausal and menopausal women. , 1984, JOGN nursing; journal of obstetric, gynecologic, and neonatal nursing.

[11]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[12]  C. J. Christy Vitamin E in menopause , 1945 .

[13]  J. O'fallon,et al.  Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Seaman,et al.  Women And The Crisis In Sex Hormones , 1977 .

[15]  R. Finkler The effect of vitamin E in the menopause. , 1949, The Journal of clinical endocrinology and metabolism.